Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026)

Precigen's (PGEN) quarterly Total Non-Current Liabilities came in at $118.3 million in Q1 2026, up 290.24% year-on-year from $30.3 million in Q1 2025, and down 12.03% on a QoQ basis from $134.5 million in Q4 2025.

Precigen (PGEN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Precigen (PGEN) has 15 years of Total Non-Current Liabilities data on file, last reported at $118.3 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 290.24% year-over-year to $118.3 million in Q1 2026; TTM through Mar 2026 was $118.3 million, a 290.24% increase from a year earlier, with the FY2025 full-year figure at $134.5 million, up 71.21% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $118.3 million, down from $134.5 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PGEN reached as high as $261.7 million in Q1 2022 and fell as low as $29.2 million in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $101.8 million across 5 years, with a median of $98.4 million in 2024.
  • Across the five-year window, Total Non-Current Liabilities climbed 12.75% in 2022 and soared 290.24% in 2026, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $261.7 million in 2022, then slumped by 87.56% to $32.5 million in 2023, then soared by 141.31% to $78.5 million in 2024, then surged by 71.21% to $134.5 million in 2025, then fell by 12.03% to $118.3 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $118.3 million in Q1 2026, $134.5 million in Q4 2025, and $129.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Precigen 1.96 Bn 1.96 Bn 20.69 Mn 118.29 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 118.29 Mn
Dec 31, 2025 134.46 Mn
Sep 30, 2025 129.40 Mn
Jun 30, 2025 29.23 Mn
Mar 31, 2025 30.31 Mn
Dec 31, 2024 78.54 Mn
Dec 31, 2023 32.55 Mn
Mar 31, 2022 261.68 Mn
Dec 31, 2021 252.46 Mn
Sep 30, 2021 245.60 Mn
Jun 30, 2021 243.33 Mn
Mar 31, 2021 232.09 Mn
Dec 31, 2020 247.31 Mn
Sep 30, 2020 277.53 Mn
Jun 30, 2020 312.07 Mn
Dec 31, 2019 88,000.00
Sep 30, 2019 376.26 Mn
Jun 30, 2019 375.74 Mn
Mar 31, 2019 374.38 Mn
Dec 31, 2018 334.32 Mn